1. Role: Associate Dean. Scope: College. Description: Lead research enterprise of the College of Pharmacy. Represent the College at the HSC level. Mentor researchers. Date: 2020.
Vibhudutta Awasthi, Ph.D.
Professor and Associate Dean for Research
Pharmaceutical Sciences
Phone (405) 271-6593 x47331
Fax (405) -271-7505
Office CPB 309
Summary
My research interests are in the development of radiopharmaceuticals, small animal imaging and use of radiological imaging techniques to answer physiological questions. My current research focuses on the development of liposome encapsulated hemoglobin as an artificial oxygen carrier and he is studying cerebral oxygen metabolism using positron emission tomography. I am a board certified nuclear pharmacist with expertise in areas related to drug delivery, formulation development, nuclear pharmacy and small animal nuclear imaging.
Publications & Presentations
- 6. Awasthi V, Gali H, Hedrick A F, Da H, Eeda V, Jain D. Positron Emission Tomography (PET) with (18)F-FGA for Diagnosis of Myocardial Infarction in a Coronary Artery Ligation Model. Molecular imaging. 2022; 2022 : 9147379
7. Awasthi S, Kumar G, Ramani V, Awasthi V, Rodgers K K, Xie J, Beierle J, Kyere-Davies G, Singh B, Rahman N, Chowdhury A A, Chataut N. Mechanism of Anti-Inflammatory Activity of TLR4-Interacting SPA4 Peptide. ImmunoHorizons. 2021; 5 : 659-674
8. Awasthi V, Bulotta S, Cosco D. Bypassing the Biological Barriers by Means of Biocompatible Drug Delivery Systems. Front. Pharmacol. - Experimental Pharmacology and Drug Discovery. 2021; 12 : 801383
9. Eeda V, Hedrick A, Awasthi V. Design of 99mTc-labeled Zinc-chelating imaging Probe for SPECT imaging of the pancreas. Bioorg Med Chem Lett. 2021; 52 : 128385
10. Eeda V, Hedrick A, Awasthi V. Design of (99m)Tc-labeled zinc-chelating imaging probe for SPECT imaging of the pancreas. Bioorganic & medicinal chemistry letters. 2021; 52 : 128385
Grants
- 1. Mechanism of F-18-fluorodeoxyglucarate accrual in myocardial injury. NHLBI. Start Date: 2024. End Date: 2029.
2. Developing PPARĪ³ acetylation inhibitor for the treatment of aging-related conditions. NIH. Start Date: 2021. End Date: 2026.
3. Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment. NIH. Start Date: 2021. End Date: 2026.
4. SBIR Phase I: Early-Stage Development of GPPD for Fatty Liver. NIH.
5. Surfactant protein-A regions as TLR4-immunomodulators. NIH. Start Date: 2017. End Date: 2023.
Awards and Honors
- 1. USPTO. Patent application issued. Date: 2015.
2. Indo-American Society of Nuclear Medicine (IASNM)Outstanding Presidential Award . Date: 2015.
3. Journal of Pharmaceutical Sciences. Article selected as a featured research paper. Date: 2015.
4. OUHSC-College of Pharmacy. USP Convention Voting Delegate. Date: 2014.
5. Robert Glenn Rapp Foundation. Presidential Professor . Date: 2013.
Education
- 1. Degree: Ph D. Sanjay Gandhi Postgraduate Institute of Medical Sciences . Date: 1994.
2. Degree: M. Pharm.. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1990.
3. Degree: B. Pharm. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1988.
Administrative Assignments
2. Role: Director. Scope: University. Description: Direction and conduct of nuclear imaging services for biomedical investigators; Production of PET radiotracers for preclinical imaging and preparation for regulatory compliance for clinical applications; Consultations with researchers about imaging and tracer applications. Date: 2007.
External Connections and Partnerships
no results